
Abraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 becoming the standard second-line treatment in lung cancer.

Published: December 2nd 2015 | Updated:

Published: November 13th 2014 | Updated: